Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - ondansetron - solution for inj/inf - 2 mg/ml - ondansetron

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 20 mg - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).

United States - English - NLM (National Library of Medicine)

hospira, inc. - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved